Arcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report released on Tuesday. The firm set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Arcadia Biosciences in a research report on Friday, April 5th.

Arcadia Biosciences Stock Performance

NASDAQ:RKDA opened at $2.00 on Tuesday. The firm has a 50-day simple moving average of $2.25 and a 200-day simple moving average of $2.68. Arcadia Biosciences has a one year low of $1.85 and a one year high of $7.30. The firm has a market cap of $2.71 million, a P/E ratio of -0.14 and a beta of 0.62.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings data on Thursday, March 28th. The basic materials company reported ($2.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.68) by $0.20. The company had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.80 million. Arcadia Biosciences had a negative net margin of 246.80% and a negative return on equity of 81.56%. On average, research analysts predict that Arcadia Biosciences will post -5.01 EPS for the current fiscal year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.